GATA binding protein 6 (GATA6) (GATA6)

GATA binding protein 6 (GATA6) is a member of the GATA family of zinc-finger transcription factors, essential for the embryonic development of endoderm-derived organs such as the heart, pancreas, and gut (UniProt Q92908). It functions by binding to specific DNA consensus sequences to regulate the transcription of genes involved in cell differentiation and lineage specification (NCBI Gene: 2627). In the context of human disease, GATA6 mRNA expression is a pivotal biomarker in pancreatic ductal adenocarcinoma (PDAC), where it distinguishes the 'classical' molecular subtype from the more aggressive 'basal-like' subtype (PubMed: 21460852). Loss-of-function mutations in the GATA6 gene are associated with severe developmental conditions, including pancreatic agenesis and congenital heart defects (PubMed: 23348838). While the GATA6 protein is traditionally difficult to target with small molecules, its mRNA represents an alternative therapeutic target for RNA-based interventions. Experimental strategies such as RNA interference (RNAi) and antisense oligonucleotides (ASOs) are being investigated to downregulate GATA6 expression in cancers where it acts as an oncogenic driver (PubMed: 31515464). However, the broad biological requirement for GATA6 in maintaining adult tissue homeostasis, particularly in the pancreas and heart, poses significant safety challenges for systemic therapeutic inhibition. Monitoring GATA6 mRNA levels is increasingly used in clinical research to predict patient response to chemotherapy and to guide personalized treatment strategies in gastrointestinal malignancies.

Other names

GATA-binding factor 6Transcription factor GATA-6GATA6 mRNA

Degradation of GATA6 mRNA via RNA interference (RNAi) or antisense oligonucleotides (ASOs) to prevent translation of the GATA6 protein (PubMed: 31515464).